"""
Question: 1101 

Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. The Pol gene (Reverse transcriptase and protease) was amplified and sequenced to identify the genotypes and DR profiles among LLV patients in 2021.

Rationale: The study prospectively collected and analyzed patient samples and questionnaires from 2021 in Jiangsu Province, indicating it reports original, previously unpublished data rather than a re-analysis of existing datasets.

Answer: Yes
"""

"""
Question: 1102 

Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples, Pol genes of 255 patients were obtained. Phylogenetic tree was constructed from 242 pol gene sequences of LLV patients in Jiangsu province and reference sequences by FastTree software.

Rationale: The paper explicitly states it sequenced HIV pol genes from patient plasma and used those sequences for phylogenetic analysis, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. The Pol gene (Reverse transcriptase and protease) was amplified and sequenced to identify the genotypes and DR profiles among LLV patients in 2021.

Rationale: The methods describe only clinical sample sequencing and computational resistance analysis without any mention of laboratory in vitro passage experiments, indicating no such experiments were performed or reported.

Answer: No
"""

"""
Question: 1104 

Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades: sensitive, potential resistance, low-level resistance, moderate-level resistance, and high-level resistance.

Rationale: The study used genotypic resistance interpretation (Stanford HIVdb) rather than laboratory phenotypic susceptibility testing, so it does not report novel in vitro antiretroviral susceptibility data.

Answer: No
"""

"""
Question: 2101 

Evidence: The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Rationale: Although the paper states accession numbers exist in the article/Supplementary Material, it does not specify GenBank accession numbers in the provided text, so this cannot be confirmed from the text given.

Answer: NA
"""

"""
Question: 2102 

Evidence: The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Rationale: The text indicates accession numbers are available somewhere but does not specify whether they are GenBank or related to non-laboratory isolates; therefore, this cannot be determined from the provided content.

Answer: NA
"""

"""
Question: 2103 

Evidence: The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Rationale: No specific accession numbers are provided in the text, only a statement that they are available elsewhere, so the requested accession numbers cannot be listed.

Answer: NA
"""

"""
Question: 2202 

Evidence: The DRM sites and corresponding drug sensitivity of 98 patients with drug resistance are shown in the Supplementary Materials. According to the drug resistance analysis results, 66 drug resistance mutation (DRM) sites were detected in 98 patients with drug resistance.

Rationale: The paper explicitly notes that per-patient mutation lists and drug sensitivities are provided in the Supplementary Materials, indicating that lists of mutations for individual sequenced isolates were reported.

Answer: Yes
"""

"""
Question: 2301 

Evidence: HIV-1 Drug Resistance Profiles of Low-Level Viremia Patients and Factors Associated With the Treatment Effect of ART-Treated Patients: A Cross-Sectional Study in Jiangsu, China. Ten HIV-1 genotypes were detected based on the Pol gene fragments from 242 cases.

Rationale: The title and genotype description both specify HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Ten HIV-1 genotypes were detected based on the Pol gene fragments from 242 cases. The proportion from high to low were as follows: Circulating Recombinant Forms (CRF) 01_AE, CRF07_BC, B, CRF67_01B, CRF08_BC, CRF55_01B, CRF68_01B, 01BC, 0107 and CRF65_cpx.

Rationale: The paper lists all detected subtypes/CRFs among the sequenced viruses.

Answer: CRF01_AE, CRF07_BC, subtype B, CRF67_01B, CRF08_BC, CRF55_01B, CRF68_01B, 01BC (URF), 0107 (URF), CRF65_cpx
"""

"""
Question: 2303 

Evidence: The Pol gene (Reverse transcriptase and protease) was amplified and sequenced to identify the genotypes and DR profiles among LLV patients in 2021. Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method.

Rationale: The methods specify sequencing of the HIV pol gene, specifically the reverse transcriptase and protease regions.

Answer: Pol gene (reverse transcriptase and protease regions)
"""

"""
Question: 2304 

Evidence: Pol genes of 255 patients were obtained. Phylogenetic tree was constructed from 242 pol gene sequences of LLV patients in Jiangsu province and reference sequences by FastTree software.

Rationale: The study reports results obtained from HIV pol sequences, including phylogenetic analysis.

Answer: Yes
"""

"""
Question: 2401 

Evidence: HIV-1 Drug Resistance Profiles of Low-Level Viremia Patients ...: A Cross-Sectional Study in Jiangsu, China. A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021.

Rationale: The sequences were from Jiangsu Province, China.

Answer: Jiangsu Province, China
"""

"""
Question: 2402 

Evidence: In this study, a total of 345 samples were collected throughout 2021. A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021.

Rationale: The text clearly states that the samples were collected and analyzed in 2021.

Answer: 2021
"""

"""
Question: 2502 

Evidence: PCR products were sent to Sangon Biotech for sequencing. ChromasPro (Version: 1.6) was used for sequence spliced.

Rationale: The sequencing platform type (e.g., Sanger) is not explicitly stated; therefore, whether Sanger was used cannot be determined from the provided text.

Answer: NA
"""

"""
Question: 2503 

Evidence: PCR products were sent to Sangon Biotech for sequencing. ChromasPro (Version: 1.6) was used for sequence spliced.

Rationale: No next-generation sequencing platform or methods are mentioned; the workflow described is consistent with conventional PCR and direct sequencing rather than NGS.

Answer: No
"""

"""
Question: 2504 

Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. PCR products were sent to Sangon Biotech for sequencing.

Rationale: There is no mention of molecular cloning of amplicons prior to sequencing; however, the absence of explicit detail means this cannot be confirmed definitively.

Answer: NA
"""

"""
Question: 2505 

Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. PCR products were sent to Sangon Biotech for sequencing.

Rationale: The study describes bulk PCR amplification and direct sequencing of plasma RNA; there is no indication of single-genome sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. PCR products were sent to Sangon Biotech for sequencing.

Rationale: The methods do not describe molecular cloning; they describe PCR amplification and direct sequencing.

Answer: No
"""

"""
Question: 2601 

Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples. Pol genes of 255 patients were obtained.

Rationale: The text explicitly states plasma was used for sequencing, confirming plasma HIV sequencing.

Answer: Yes
"""

"""
Question: 2602 

Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples. Pol genes of 255 patients were obtained.

Rationale: The paper only mentions plasma sequencing; there is no mention of PBMC sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples. Pol genes of 255 patients were obtained.

Rationale: Sequencing was performed on plasma from 345 samples, although only 242 sequences met inclusion; the question asks how many underwent plasma sequencing, which is 345.

Answer: 345
"""

"""
Question: 2604 

Evidence: After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples. Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method.

Rationale: PBMC sequencing is not described anywhere; therefore, the number of PBMC-sequenced samples is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: According to WHO guidelines, LLV is defined as viral load (VL) between 50 and 1,000 copies/ml. Inclusion criteria included ... VL was in the range of 50--1,000 copies/ml during follow-up.

Rationale: Detectable plasma viral loads indicate ongoing active HIV replication; hence, sequences were obtained from individuals with active replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: PCR amplification and sequencing were performed on the plasma of 345 samples. The Pol gene (Reverse transcriptase and protease) was amplified and sequenced.

Rationale: Sequencing was performed on plasma RNA, not on cellular proviral DNA; therefore, sequences were not obtained from the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: Inclusion criteria included: (2) The subjects were older than 18 years at follow-up. Inclusion criteria were: (1) age 18 and above.

Rationale: Only adults (≥18 years) were included; there were no infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. Voluntarily participate in the program and give informed consent.

Rationale: The study is observational (cross-sectional and case-control) and not a clinical trial; no trial enrollment is described.

Answer: No
"""

"""
Question: 2703 

Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. Voluntarily participate in the program and give informed consent.

Rationale: As the study was not a clinical trial, it follows that not all individuals were in a trial.

Answer: No
"""

"""
Question: 3101 

Evidence: In this study, a total of 345 samples were collected throughout 2021. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples.

Rationale: The number of individuals with samples obtained for sequencing corresponds to the 345 collected and processed plasma samples.

Answer: 345
"""

"""
Question: 3102 

Evidence: Pol genes of 255 patients were obtained. Thirteen cases of sequences with poor quality or unmatched information were removed, and 242 cases of sequences meeting the research requirements were finally included.

Rationale: Not all individuals had successful or included sequences; only 242 were included, indicating incomplete sequencing coverage.

Answer: No
"""

"""
Question: 4101 

Evidence: Inclusion criteria included: (3) ART time at follow-up was more than 6 months. Inclusion criteria were: (4) the treatment duration was more than half a year (≥180 days) at the time of follow-up.

Rationale: All sequenced participants were ART-experienced (≥6 months), so there were no ART-naive individuals.

Answer: No
"""

"""
Question: 4102 

Evidence: Inclusion criteria included: (3) ART time at follow-up was more than 6 months. Inclusion criteria were: (4) the treatment duration was more than half a year (≥180 days) at the time of follow-up.

Rationale: The inclusion criteria required ongoing ART, indicating sequences are from individuals who had previously received ARV drugs.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Inclusion criteria included: (3) ART time at follow-up was more than 6 months. Inclusion criteria were: (5) Patients in the case group were 50--1,000 copies/ml ... while patients in the control group were VS patients (VL<50 copies/ml).

Rationale: All participants were ART-experienced; there is no ART-naive group described, so the study does not include both ART-naive and ART-experienced sequences.

Answer: No
"""

"""
Question: 4104 

Evidence: Inclusion criteria included: (3) ART time at follow-up was more than 6 months. Inclusion criteria were: (4) the treatment duration was more than half a year (≥180 days) at the time of follow-up.

Rationale: Because ART-naive individuals were not eligible, the count of samples from ART-naive individuals is zero.

Answer: 0
"""

"""
Question: 4105 

Evidence: It is worth noting that this study was a cross-sectional study within 1 year; the treatment regimen of patients was identified as the one adopted at the follow-up time point, and the DR of patients may not have been generated during the use of the current regimen. However, this study did not obtain data on previous regimen changes and DR profiles of patients.

Rationale: The authors explicitly state they lack prior regimen change data and earlier DR profiles, indicating incomplete ART histories.

Answer: No
"""

"""
Question: 4201 

Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. Inclusion criteria included ... ART time at follow-up was more than 6 months; VL was in the range of 50--1,000 copies/ml during follow-up.

Rationale: The study focuses on ART-experienced LLV patients rather than newly infected or untreated individuals; hence, it does not address transmitted drug resistance prevalence.

Answer: No
"""

"""
Question: 4202 

Evidence: Inclusion criteria were ... the treatment duration was more than half a year (≥180 days) at the time of follow-up. Patients in the case group were 50--1,000 copies/ml ... while patients in the control group were VS patients (VL<50 copies/ml).

Rationale: The study population is not pretreatment (they are on ART), so pretreatment HIV drug resistance prevalence is not reported.

Answer: No
"""

"""
Question: 4301 

Evidence: The treatment regimens were divided into four categories. Patients using the 2NRTIs+NNRTIs regimen ... patients using the 2NRTIs+PIs regimen ... patients using the 2NRTIs+INSTIs regimen.

Rationale: The regimens described indicate that participants received combinations including NRTIs with NNRTIs, PIs, or INSTIs.

Answer: NRTIs, NNRTIs, PIs, INSTIs
"""

"""
Question: 4302 

Evidence: The treatment regimens were divided into four categories. 2NRTIs+INSTIs appears as one of the categories and was used by some patients.

Rationale: The presence of a 2NRTIs+INSTIs regimen indicates that some individuals received integrase inhibitors.

Answer: Yes
"""

"""
Question: 4303 

Evidence: The treatment regimens were divided into four categories. 2NRTIs+PIs appears as one of the categories and was used by some patients.

Rationale: The inclusion of a PI-based regimen confirms that some individuals received protease inhibitors.

Answer: Yes
"""

"""
Question: 4304 

Evidence: The treatment regimens were divided into four categories. The majority of patients received 2NRTIs+NNRTIs at follow-up, followed by 2NRTIs+PIs and 2NRTIs+INSTIs.

Rationale: Multiple distinct ART regimen categories were used; therefore, not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: The treatment regimens were divided into four categories. 2NRTIs+INSTIs appears as one of the categories and was used by some patients.

Rationale: Because some patients received INSTI-containing regimens, not all individuals were INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: the treatment regimen of patients was identified as the one adopted at the follow-up time point, and the DR of patients may not have been generated during the use of the current regimen. However, this study did not obtain data on previous regimen changes and DR profiles of patients.

Rationale: The paper lacks data on prior regimen changes, so it is not possible to determine how many individuals received more than one ART regimen.

Answer: NA
"""

"""
Question: 4404 

Evidence: the treatment regimen of patients was identified as the one adopted at the follow-up time point. However, this study did not obtain data on previous regimen changes and DR profiles of patients.

Rationale: Without prior regimen histories, the number who received more than two regimens cannot be determined.

Answer: NA
"""

"""
Question: 4405 

Evidence: the treatment regimen of patients was identified as the one adopted at the follow-up time point. However, this study did not obtain data on previous regimen changes and DR profiles of patients.

Rationale: The paper does not report the number of regimens per individual, so whether all received the same number of regimens is unknown.

Answer: NA
"""

"""
Question: 4406 

Evidence: the treatment regimen of patients was identified as the one adopted at the follow-up time point. However, this study did not obtain data on previous regimen changes and DR profiles of patients.

Rationale: Because the study did not collect prior regimen histories, it cannot be determined whether all individuals received only one regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: The treatment regimens were divided into four categories. Patients using the 2NRTIs+INSTIs regimen accounted for a small proportion.

Rationale: Although INSTI-based regimens are mentioned, specific drugs like dolutegravir are not enumerated; therefore, the number of individuals receiving dolutegravir is not reported.

Answer: NA
"""

"""
Question: 4502 

Evidence: The treatment regimens were divided into four categories. The paper does not list specific PI drugs used in patients’ regimens.

Rationale: While resistance predictions include various PIs (including DRV) in Table 4, actual patient receipt of darunavir is not reported; therefore, the number cannot be determined.

Answer: NA
"""

"""
Question: 5101 

Evidence: There are 98 drug resistance sequences among 242 pol genes (low or above level resistance to any class of drugs). According to the drug resistance analysis results, 66 drug resistance mutation (DRM) sites were detected in 98 patients with drug resistance.

Rationale: The paper states 98 sequences had drug resistance (i.e., at least one DRM), so 98 individuals had one or more DRMs.

Answer: 98
"""

"""
Question: 5102 

Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. Seventeen patients developed DRM sites associated with PIs drugs, and 14 patients had low or above level resistance, with extensive reporting on NRTIs- and NNRTIs-related DRM sites.

Rationale: The integrase gene was not sequenced or analyzed, and no INSTI-resistance mutations were reported.

Answer: NA
"""

"""
Question: 5103 

Evidence: Sixty-six of the 98 patients had NRTIs-related DRM sites, and all caused low or above level drug resistance. The DRM sites and corresponding drug sensitivity of 98 patients with drug resistance are shown in the Supplementary Materials.

Rationale: Although TDF resistance is summarized in Table 4, the exact count of individuals with TDF-resistance mutations is not explicitly stated in the narrative text; hence, from the provided text, it cannot be determined definitively.

Answer: NA
"""

"""
Question: 5104 

Evidence: Target genes in the Pol region (Reverse transcriptase and protease) were amplified by the in-house method. According to the drug resistance analysis results, DRM sites reported pertain to NRTIs, NNRTIs, and PIs regions.

Rationale: The integrase region was not sequenced; therefore, no INSTI-resistance mutations were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database (https://hivdb.Stanford.edu/) for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.

Rationale: The study used genotypic interpretation rather than any phenotypic susceptibility assay; hence, no phenotypic method was used.

Answer: NA
"""

"""
Question: 6102 

Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.

Rationale: The paper does not report in vitro IC metrics (e.g., IC50, IC90); it relies on genotypic resistance scoring.

Answer: No
"""

"""
Question: 6103 

Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.

Rationale: No phenotypic fold-change data (e.g., IC50 fold change) are presented.

Answer: No
"""

"""
Question: 6104 

Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.

Rationale: No phenotypic susceptibility assay was used or reported; only genotypic analysis was performed.

Answer: NA
"""

"""
Question: 6105 

Evidence: The study tested the drug resistance of LLV patients who were followed up in Jiangsu province in 2021. Pol region sequences were uploaded to the HIV Drug Resistance Database for drug resistance analysis.

Rationale: The paper does not report replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: Pol region sequences were uploaded to the HIV Drug Resistance Database for drug resistance analysis. The drug resistance degree of each drug was divided into five grades.

Rationale: No phenotypic testing was conducted; therefore, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: The Pol gene (Reverse transcriptase and protease) was amplified and sequenced to identify the genotypes and DR profiles among LLV patients in 2021. After nucleic acid extraction, PCR amplification and sequencing were performed on the plasma of 345 samples.

Rationale: All sequences were patient-derived from plasma; there is no mention of site-directed mutant constructs.

Answer: No
"""

"""
Question: 7102 

Evidence: A cross-sectional study design was used to study the DR profiles in LLV patients who were followed up in Jiangsu Province in 2021. The Pol gene (Reverse transcriptase and protease) was amplified and sequenced to identify the genotypes and DR profiles among LLV patients in 2021.

Rationale: The study did not include any in vitro passage experiments; it focused on sequencing clinical samples.

Answer: No
"""